drugset / Trial / NCT05991232

Repeated Neurocognitive Measurements in Depressed Patients

NCT05991232 ↗

Phase 1/2 Withdrawn Jay Fournier
NaSingle-groupOpen-labelBasic science

Summary

In this project, we will A) track the functioning of a collection of potential neurobiological targets for depression over time, B) examine how fluctuations in the functioning of those targets relates to real-world functioning, and C) in a subset of the sample, determine how the functioning in those targets is altered by a single dose of ketamine.

Timeline

Start
2025-05-01
Primary completion
2028-04
Completion
2029-04

Outcome

Outcome not reported

Stopped (Enrollment): “This study never started enrollment at this site. Delays in establishing the infrastructure for this project resulted in the funds no longer being available at this time. Should additional funds be secured, a separate study will be registered here.”

Drugs

EvaluationDrugModalityDoseRoute
Subject Ketamine Small molecule 0.5 mg/kg Intravenous

Indications